Synchron Advances Ahead of Neuralink with Large-Scale Clinical Trial for Minimally Invasive Brain-Computer Interface

Brain-Computer Interface Startup Synchron Recently Revealed That It Is Preparing to Recruit Patients for Large-Scale Clinical Trials, Aiming to Advance the Commercialization and Clinical Application of Its Brain Implant Device.

Synchron CEO Thomas Oxley stated in a recent interview that the company plans to launch an online registration service on Monday (April 8) to recruit patients interested in participating in the trial, with a target of enrolling dozens of participants. Synchron has received expressions of interest or intent from approximately 120 clinical trial sites to help conduct this study, as they aim to support the advancement of this research.

Oxley added, “The open online registration service is designed to facilitate communication between physicians and patients with movement disorders, enabling doctors to assess patients’ conditions and provide them with relevant information about upcoming clinical trials. This ensures that preparations proceed smoothly, avoiding chaos or delays caused by an excessive number of participants before the trial begins.”

In the field of brain-computer interfaces, Neuralink, founded by billionaire Elon Musk, is the most well-known; however, Synchron has actually advanced further in testing its brain implant devices. Both companies initially aimed to help paralyzed patients type on computers using devices capable of decoding brain signals.

Synchron, Inc. was founded in 2012 and received authorization for initial testing in the United States in July 2021. The company has implanted its device in six patients, with no serious adverse side effects reported among the subjects.

Neuralink, founded in 2016, did not see its first human patient receive a brain implant until January of this year. The subject has now fully recovered and is able to play video games and online chess using only their thoughts.

Furthermore, Neuralink’s brain-computer interface device is an invasive brain implant that controls external devices via neural signals, thereby helping patients with severe paralysis regain the ability to communicate with the outside world. In contrast, Synchron employs a less invasive and more accessible implantation method, built upon existing endovascular technologies, which can be achieved through minimally invasive surgery alone.

Oxley stated that they would analyze prior data to prepare for larger-scale studies while awaiting approval from the U.S. Food and Drug Administration (FDA). The experimental targets are patients paralyzed due to amyotrophic lateral sclerosis, stroke, and multiple sclerosis.

Currently, Mount Sinai Hospital in New York, the University at Buffalo, and the University of Pittsburgh Medical Center are collaborating with Synchron on preliminary studies and hope to participate in larger-scale trials.

Dr. David Lacomis, Director of the Neuromuscular Division at the University of Pittsburgh Medical Center, stated that his team remains involved in preliminary testing, with research progressing smoothly and substantial data being collected, while planning for larger-scale pivotal trials is underway. “We will continue to monitor the safety of study participants and collect extensive data during the use of the brain implant.”

Kip Ludwig, former program director at the National Institutes of Health, stated: “Synchron aims to expand its market to include individuals who have suffered strokes severe enough to cause paralysis, because if limited solely to quadriplegia, the market would be too small for sustainable growth.”